Detection of a Small Insulinoma Using a Novel Glucagon-Like Peptide-1 Receptor Ligand

Detection of a Small Insulinoma Using a Novel Glucagon-Like Peptide-1 Receptor Ligand

Bibliographic Details
Main Author:	Sara K. Meibom, MD
Format:	Article
Language:	English
Published:	Elsevier 2015-01-01
Series:	AACE Clinical Case Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2376060520302558

Similar Items

Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas
by: Tiina Vesterinen, et al.
Published: (2023-10-01)

Insulinoma Localization by Glucagon-Like Peptide-1 Receptor Imaging After 18 Years of Hypoglycemia
by: Aglaia Kyrilli, MD, et al.
Published: (2015-01-01)

Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
by: Mi Yeon Kang, et al.
Published: (2015-06-01)

Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain.
by: Graham M West, et al.
Published: (2014-01-01)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017-03-01)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
by: Samantha L. Price, MRes, et al.
Published: (2015-12-01)

Structural and Molecular Conservation of Glucagon-like Peptide-1 and Its Receptor Confers Selective Ligand-Receptor Interaction
by: Mi Jin eMoon, et al.
Published: (2012-11-01)

Equine glucagon-like peptide-1 receptor physiology
by: Murad H. Kheder, et al.
Published: (2018-01-01)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
by: Gurung T, et al.
Published: (2015-08-01)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
by: Mariya Kalinkova, et al.
Published: (2023-06-01)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
by: Yu Mi Kang, et al.
Published: (2016-06-01)

How glucagon-like peptide 1 receptor agonists work
by: Christine Rode Andreasen, et al.
Published: (2021-07-01)

99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma.
by: Anna Sowa-Staszczak, et al.
Published: (2016-01-01)

Discrepancy between the Actions of Glucagon-like Peptide-1 Receptor Ligands in the Protection of the Heart against Ischemia Reperfusion Injury
by: Ali Ismaeil, et al.
Published: (2022-06-01)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
by: Markus Ammann, et al.
Published: (2023-09-01)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
by: A. Delgado, et al.
Published: (2021-04-01)

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
by: Magda Wojtara, et al.
Published: (2023-01-01)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
by: Frederik Flindt Kreiner, et al.
Published: (2022-09-01)

Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
by: Fuxun Yang, et al.
Published: (2022-08-01)

Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis
by: Marwa R. Al-Badri, et al.
Published: (2014-04-01)

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.
by: Aiysha Thompson, et al.
Published: (2016-01-01)

New insights into the regulation of glucagon secretion by glucagon-like peptide-1.
by: Gromada, J, et al.
Published: (2004)

Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
by: Dimitrios Patoulias, MD, et al.
Published: (2021-07-01)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
by: Daria Ja’arah, et al.
Published: (2021-10-01)

Glucagon-like peptide 1 (GLP-1)
by: T.D. Müller, et al.
Published: (2019-12-01)

Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain
by: Yolanda Diz-Chaves, et al.
Published: (2024-01-01)

Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy
by: Chunyan Liu, et al.
Published: (2024-01-01)

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021-08-01)

Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor
by: Anna K. O. Rode, et al.
Published: (2022-08-01)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
by: Giuseppe Lisco, et al.
Published: (2023-10-01)

Clinical impact of Glucagon like peptide-1 receptor analogs on the complications of obesity
by: Dilek Yazıcı, et al.
Published: (2022-11-01)

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
by: Laurie L. Baggio, et al.
Published: (2021-04-01)

The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies
by: Peng Jiang, et al.
Published: (2024-05-01)

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
by: Agnieszka Jakubowska, et al.
Published: (2024-02-01)

In Reply to ‘Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?’
by: David J. Leehey, MD
Published: (2021-07-01)

Structural Modeling and in Silico Screening of Potential Small-Molecule Allosteric Agonists of a Glucagon-like Peptide 1 Receptor
by: Tejashree Redij, et al.
Published: (2019-01-01)

Potential of a glucagon‐like peptide‐1 receptor/glucose‐dependent insulinotropic polypeptide receptor/glucagon receptor triagonist for the treatment of obesity and type 2 diabetes
by: Eiichi Araki, et al.
Published: (2022-12-01)